Botulinum toxin for treatment of urinary incontinence due to detrusor overactivity: A systematic review of effectiveness and adverse effects

Spinal Cord

Volumn 45, Issue 8, 2007, Pages 535-541

  MacDonald, R ^a   Fink, H A ^a   Huckabay, C ^a   Monga, M ^a   Wilt, T J ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Minneapolis Veterans Affairs Center for Chronic Disease Outcomes Research   (United States)

Author keywords

Botulinum toxin; Detrusor overactivity; Spinal cord injury; Systematic review; Urinary incontinence

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B; PLACEBO; RESINIFERATOXIN;

ARTICLE; AUTONOMIC DYSFUNCTION; AUTONOMIC DYSREFLEXIA; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DETRUSOR DYSSYNERGIA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; HEMATURIA; HUMAN; INJECTION SITE PAIN; MALAISE; PATHOGENESIS; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL; SPINAL CORD INJURY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; URINARY TRACT INFECTION; URINE INCONTINENCE; URINE RETENTION; XEROSTOMIA;

BOTULINUM TOXINS; HUMANS; RANDOMIZED CONTROLLED TRIALS; SPINAL CORD INJURIES; TREATMENT OUTCOME; URINARY BLADDER, NEUROGENIC; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE;

EID: 34547631451     PISSN: 13624393     EISSN: 14765624     Source Type: Journal    
DOI: 10.1038/sj.sc.3102070     Document Type: Article

References (24)

1. Jackson S. The patient with an overactive bladder - symptoms and quality-of-life issues. Urology 1997; 50: 18-22.
2. Chapple C, Khullar V, Gabriel Z, Dooley JA. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 2005; 48: 5-26.
3. de Seze M, Wiart L, Joseph PA, Dosque JP, Mazaux JM, Barat M. Capsaicin and neurogenic detrusor hyperreflexia: a double-blind placebo-controlled study in 20 patients with spinal cord lesions. Neurourol Urodyn 1998; 17: 513-523.
4. Giannantoni A et al. Intravesical capsaicin versus resiniferatoxin in patients with detrusor hyperreflexia: a prospective randomized study. J Urol 2002; 167: 1710-1714.
5. Kim JH et al. Intravesical resiniferatoxin for refractory detrusor hyperreflexia: a multicenter, blinded, randomized, placebo-controlled trial. J Spinal Cord Med 2003; 26: 358-363.
6. Reitz A et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004; 45: 510-515.
7. Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000; 164: 692-697.
8. Hallett M. One man's poison - clinical applications of botulinum toxin. N Engl J Med 1999; 341: 118-120.
9. Sheean G. Botulinum toxin forthe treatment of musculoskeletal pain and spasm. Curr Pain Headache Rep 2002; 6: 460-469.
10. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies forsystematic reviews. BMJ 1994; 309: 1286-1291.
11. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408-412.
12. Review Manager. [Computer program]: Version 4.1 for Windows. The Cochrane Collaboration: Oxford, England 2001.
13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
14. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ 2003; 327: 557-560.
15. Schurch B et al. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005; 174: 196-200.
16. Giannantoni A, Di Stasi SM, Stephen RL, Bini V, Costantini E, Porena M. Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J Urol 2004; 172: 240-243.
17. Ghei M et al. Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial. J Urol 2005; 174: 1873-1877.
18. Reitz A, Schurch B. Botulinum toxin type B injection for management of type A resistant neurogenic detrusor overactivity. J Urol 2004; 171: 804-805.
19. Kuo HC. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology 2004; 63: 868-872.
20. Kessler TM, Danuser H, Schumacher M, Studer UE, Burkhard FC. Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity? Neurourol Urodyn 2005; 24: 231-236.
21. Leippold T, Reitz A, Schurch B. Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Eur Urol 2003; 44: 165-174.
22. www.drugstore.com (August 2006).
23. Del Popolo G. Botulinum toxin A in the treatment of detrusor hyperreflexia. Neurourol Urodyn 2001; 20: 522-524.
24. Wyndaele JJ, Van Dromme SA. Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord 2002; 40: 599-600.